JP2022532790A5 - - Google Patents
Info
- Publication number
- JP2022532790A5 JP2022532790A5 JP2021568766A JP2021568766A JP2022532790A5 JP 2022532790 A5 JP2022532790 A5 JP 2022532790A5 JP 2021568766 A JP2021568766 A JP 2021568766A JP 2021568766 A JP2021568766 A JP 2021568766A JP 2022532790 A5 JP2022532790 A5 JP 2022532790A5
- Authority
- JP
- Japan
- Prior art keywords
- ray
- powder
- peaks
- compound according
- diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025080319A JP2025131597A (ja) | 2019-05-21 | 2025-05-13 | 固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851049P | 2019-05-21 | 2019-05-21 | |
| US62/851,049 | 2019-05-21 | ||
| PCT/US2020/033832 WO2020236948A1 (en) | 2019-05-21 | 2020-05-20 | Solid state forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025080319A Division JP2025131597A (ja) | 2019-05-21 | 2025-05-13 | 固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532790A JP2022532790A (ja) | 2022-07-19 |
| JP2022532790A5 true JP2022532790A5 (enExample) | 2023-05-24 |
Family
ID=71016701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568766A Pending JP2022532790A (ja) | 2019-05-21 | 2020-05-20 | 固体形態 |
| JP2025080319A Pending JP2025131597A (ja) | 2019-05-21 | 2025-05-13 | 固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025080319A Pending JP2025131597A (ja) | 2019-05-21 | 2025-05-13 | 固体形態 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12252486B2 (enExample) |
| EP (1) | EP3972972A1 (enExample) |
| JP (2) | JP2022532790A (enExample) |
| AR (1) | AR119741A1 (enExample) |
| AU (2) | AU2020277398B2 (enExample) |
| CA (1) | CA3140394A1 (enExample) |
| MX (2) | MX2021014235A (enExample) |
| TW (1) | TW202110836A (enExample) |
| UY (1) | UY38711A (enExample) |
| WO (1) | WO2020236948A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2019384118B2 (en) | 2018-11-19 | 2025-06-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| AU2020277398B2 (en) | 2019-05-21 | 2026-01-29 | Amgen Inc. | Solid state forms |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4153588A1 (en) * | 2020-05-20 | 2023-03-29 | Teva Pharmaceuticals International GmbH | Solid state forms of amg-510 and process for preparation thereof |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4253376B1 (en) * | 2020-11-26 | 2025-07-30 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| JP2024518845A (ja) * | 2021-05-19 | 2024-05-07 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | ソトラシブ及びその固体状態形態の調製のためのプロセス |
| CN114605406B (zh) * | 2021-09-18 | 2023-05-26 | 都创(上海)医药开发有限公司 | Amg510化合物的晶型及其制备方法和用途 |
| CN115368358A (zh) * | 2022-09-01 | 2022-11-22 | 浙江九洲药业股份有限公司 | 一种Sotorasib新晶型及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312059D0 (en) | 2013-07-05 | 2013-08-21 | Univ Leuven Kath | Novel GAK modulators |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| AU2020277398B2 (en) | 2019-05-21 | 2026-01-29 | Amgen Inc. | Solid state forms |
| JP7837865B2 (ja) | 2019-11-14 | 2026-03-31 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改良合成法 |
| JP2023501528A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成 |
-
2020
- 2020-05-20 AU AU2020277398A patent/AU2020277398B2/en active Active
- 2020-05-20 WO PCT/US2020/033832 patent/WO2020236948A1/en not_active Ceased
- 2020-05-20 MX MX2021014235A patent/MX2021014235A/es unknown
- 2020-05-20 CA CA3140394A patent/CA3140394A1/en active Pending
- 2020-05-20 EP EP20731345.3A patent/EP3972972A1/en active Pending
- 2020-05-20 JP JP2021568766A patent/JP2022532790A/ja active Pending
- 2020-05-20 US US17/612,717 patent/US12252486B2/en active Active
- 2020-05-21 UY UY0001038711A patent/UY38711A/es not_active Application Discontinuation
- 2020-05-21 TW TW109116911A patent/TW202110836A/zh unknown
- 2020-05-21 AR ARP200101439A patent/AR119741A1/es not_active Application Discontinuation
-
2021
- 2021-11-19 MX MX2025010774A patent/MX2025010774A/es unknown
-
2025
- 2025-05-13 JP JP2025080319A patent/JP2025131597A/ja active Pending
-
2026
- 2026-01-22 AU AU2026200455A patent/AU2026200455A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532790A5 (enExample) | ||
| JP2022058395A5 (enExample) | ||
| HRP20221152T1 (hr) | Spojevi korisni u inhibiranju cdk7 | |
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| JP2021526132A5 (enExample) | ||
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2021521194A5 (enExample) | ||
| JP2023522250A5 (enExample) | ||
| EP2116246A1 (en) | Composition for treatment of pancreatic cancer | |
| CN119454706A (zh) | 治疗kras相关癌症的方法 | |
| WO2006080327A1 (ja) | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
| CN107296811B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2018534289A5 (enExample) | ||
| CN108530444B (zh) | 一种新型nampt和ido双重抑制剂及其制备方法和医药用途 | |
| JP2020536893A5 (enExample) | ||
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2022520361A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| JP7565118B2 (ja) | （ｓ，ｅ）－４－（ジメチルアミノ）－ｎ－（３－（４－（２－ヒドロキシ－１－フェネチルアミノ）－６－フェニルフロ［２，３－ｄ］ピリミジン－５－イル）フェニル）ブタ－２－エナミド遊離塩基の結晶形 | |
| JP2024514995A5 (enExample) | ||
| WO2024209717A1 (ja) | 腫瘍治療用医薬組成物 | |
| JP2018506562A5 (enExample) | ||
| JP2008501690A (ja) | がんの治療方法 | |
| RU2017133093A (ru) | Кристаллические формы соединения пирролопиридина | |
| TW201720800A (zh) | 經氯苯取代之氮雜芳基化合物 | |
| EP3492082B1 (en) | Anticancer pharmaceutical composition |